Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy

✍ Scribed by M. A. Fridrik; R. Greil; H. Hausmaninger; O. Krieger; P. Oppitz; M. Stöger; J. Klocker; M. Neubauer; W. Helm; J. Pont; B. Fazeny; M. Hudec; I. Simonitsch; T. Radaszkiewicz

• Publisher: Springer
• Year: 1997
• Tongue: English
• Weight: 174 KB
• Volume: 75
• Category: Article
• ISSN: 0939-5555
• DOI: 10.1007/s002770050330